Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,032.69

42 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,032.69 42

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508866443?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

42 matching records · $1,032.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 42 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–42 of 42.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $124.9912/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023391 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $83.4612/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947510469 CMS
Janssen Biotech, Inc. $4.7011/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884719 CMS
Janssen Biotech, Inc. $4.7011/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884725 CMS
PFIZER INC. $28.7811/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949614479 CMS
Sun Pharmaceutical Industries Inc. $17.6110/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947873237 CMS
ABBVIE INC. $64.1810/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023389 CMS
Janssen Scientific Affairs, LLC $145.8810/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887212009 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $39.1610/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947510467 CMS
ABBVIE INC. $8.0110/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023387 CMS
Sun Pharmaceutical Industries Inc. $24.9709/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947873249 CMS
Lilly USA, LLC $25.0708/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918254351 CMS
ABBVIE INC. $5.6508/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023385 CMS
Janssen Biotech, Inc. $13.5308/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884713 CMS
UCB, Inc. $16.2208/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907989833 CMS
Sun Pharmaceutical Industries Inc. $15.7507/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947873243 CMS
ABBVIE INC. $20.1207/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023383 CMS
Janssen Biotech, Inc. $8.9106/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884767 CMS
Galderma Laboratories, L.P. $15.7206/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952273275 CMS
ABBVIE INC. $23.1906/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023381 CMS
Janssen Biotech, Inc. $32.1705/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884779 CMS
Janssen Biotech, Inc. $5.5605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884773 CMS
ABBVIE INC. $23.2105/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023379 CMS
ABBVIE INC. $1.4205/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023377 CMS
GENZYME CORPORATION $29.3905/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939154567 CMS
Sun Pharmaceutical Industries Inc. $23.8005/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947873253 CMS
Genentech USA, Inc. $16.9104/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950781959 CMS
Janssen Biotech, Inc. $3.1904/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884737 CMS
Janssen Biotech, Inc. $8.3704/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884743 CMS
PFIZER INC. $20.1303/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949627103 CMS
Janssen Biotech, Inc. $5.3503/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884755 CMS
ABBVIE INC. $5.7903/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023375 CMS
Janssen Biotech, Inc. $6.4002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884731 CMS
ABBVIE INC. $26.2102/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023373 CMS
Allergan, Inc. $15.1402/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889894165 CMS
LEO Pharma Inc. $17.5002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936220751 CMS
ABBVIE INC. $25.7601/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023371 CMS
ABBVIE INC. $22.0601/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891023369 CMS
Janssen Biotech, Inc. $11.5201/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884749 CMS
Janssen Biotech, Inc. $14.0601/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884761 CMS
Janssen Biotech, Inc. $6.1501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885884707 CMS
GENZYME CORPORATION $22.0001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939154547 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,000.00 12/21/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046421373
Principal investigator 1 PFIZER INC. $403.92 12/18/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046412807
Principal investigator 1 PFIZER INC. $1,047.60 12/18/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046415043
Principal investigator 1 Incyte Corporation $1,561.20 12/04/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040667893
Principal investigator 1 Incyte Corporation $2,811.00 12/04/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040667907
Principal investigator 1 Eli Lilly and Company $10.95 11/16/2023 Non-covered Recipient Entity
PAUL GETZ MD SC
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038132001
Principal investigator 1 Incyte Corporation $232.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667741
Principal investigator 1 Incyte Corporation $42.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667757
Principal investigator 1 Incyte Corporation $159.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667773
Principal investigator 1 Incyte Corporation $58.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667789
Principal investigator 1 Incyte Corporation $85.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667799
Principal investigator 1 Incyte Corporation $548.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667815
Principal investigator 1 Incyte Corporation $58.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667829
Principal investigator 1 Incyte Corporation $232.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667843
Principal investigator 1 Incyte Corporation $232.00 11/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1040667857
Principal investigator 1 ABBVIE INC. $316.16 11/08/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998407059
Principal investigator 1 Amgen Inc. $5,905.20 11/08/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
P3 AD Adult Monotherapy Study 1 No dispute reported 06/30/2026 1029654177
Principal investigator 1 Incyte Corporation $2,853.00 11/06/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040667873
Principal investigator 1 Janssen Research & Development, LLC $4,673.00 10/28/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113861
Principal investigator 1 PFIZER INC. $2,132.00 10/21/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046424959
Principal investigator 1 Novartis Pharmaceuticals Corporation $114.37 10/09/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017191925
Principal investigator 1 Janssen Research & Development, LLC $4,424.00 09/15/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113857
Principal investigator 1 ABBVIE INC. $316.16 09/13/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998399277
Recipient Eli Lilly and Company $4,262.40 09/01/2023 Covered Recipient Physician AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038055463
Principal investigator 1 Eli Lilly and Company $30,615.84 08/23/2023 Non-covered Recipient Entity
PAUL GETZ MD SC
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038121787
Principal investigator 1 Janssen Research & Development, LLC $5,654.00 08/17/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113853
Principal investigator 1 Janssen Research & Development, LLC $2,481.00 07/14/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113849
Principal investigator 1 Janssen Research & Development, LLC $3,336.00 06/20/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113845
Principal investigator 1 ABBVIE INC. $2,592.80 06/08/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998385855
Principal investigator 1 PFIZER INC. $990.00 05/26/2023 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046440567
Principal investigator 1 Janssen Research & Development, LLC $2,817.00 05/18/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113841
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,858.07 05/17/2023 Non-covered Recipient Entity
Dundee Dermatology
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027486519
Principal investigator 1 ABBVIE INC. $2,276.64 04/12/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998377765
Principal investigator 1 Janssen Research & Development, LLC $2,886.00 03/20/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113837
Recipient Eli Lilly and Company $6,672.00 03/09/2023 Covered Recipient Physician AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038057293
Principal investigator 1 Janssen Research & Development, LLC $7,523.00 02/24/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113833
Principal investigator 1 PFIZER INC. $2,561.00 02/23/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046470911
Principal investigator 1 Eli Lilly and Company $16,863.60 02/08/2023 Non-covered Recipient Entity
PAUL GETZ MD SC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1038123481
Principal investigator 1 Eli Lilly and Company $22,081.20 01/25/2023 Non-covered Recipient Entity
PAUL GETZ MD SC
A PHASE 3 16-WEEK RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL- GROUP STUDY TO ASSESS THE IMPACT OF LEBRIKIZUMAB ON VACCINE RESPONSES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1038129867
Principal investigator 1 PFIZER INC. $1,591.20 01/25/2023 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046369901
Principal investigator 1 Janssen Research & Development, LLC $3,585.00 01/20/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113829
Principal investigator 1 Novartis Pharmaceuticals Corporation $144.12 01/15/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017193787
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,180.16 01/12/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1017236605
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,620.00 01/12/2023 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Randomized Double blind Multi center Study Assessing Short 16 Weeks and Long term Efficacy up to 1 Year Safety and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa SUNSHINE No dispute reported 06/30/2026 1017236805
Principal investigator 1 Janssen Research & Development, LLC $18,900.00 01/10/2023 Non-covered Recipient Entity
Paul Getz MD Sci
CNTO1959PSO3018 No dispute reported 06/30/2026 986113825
Principal investigator 1 PFIZER INC. $2,132.00 01/06/2023 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046374161